Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 2,386 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Progressive Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer

NCT00567190
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Pertuzumab, Placebo, Trastuzumab, Docetaxel
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
159
States / cities
Scottsdale, Arizona • Jonesboro, Arkansas • Alhambra, California + 120 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 29, 2026, 5:58 PM EDT
Completed Phase 1 Interventional

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

NCT04155710
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
IOV-2001, Low dose IL-2, High dose IL-2, IL-2
Biological · Drug
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Tampa, Florida • Durham, North Carolina • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 29, 2026, 5:58 PM EDT
Completed Phase 2 Interventional Results available

Monthly SOM230C for Recurrent or Progressive Meningioma

NCT00859040
View directory record Official record
Conditions
Meningioma
Interventions
SOM230C
Drug
Lead sponsor
Patrick Y. Wen, MD
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Oct 29, 2026, 5:58 PM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children

NCT02885324
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma, Malignant Brain Tumor, High Grade Glioma
Interventions
Cabozantinib
Drug
Lead sponsor
Indiana University
Other
Eligibility
2 Years to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 29, 2026, 5:58 PM EDT
Completed Phase 2 Interventional Results available

Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis

NCT02024555
View directory record Official record
Conditions
Sarcoidosis; Antimycobacterial Therapy
Interventions
Levofloxacin, Ethambutol, Azithromycin, Rifampin, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Albany, New York • Cincinnati, Ohio • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 29, 2026, 5:58 PM EDT
Completed Not applicable Interventional Results available

Shockwave, Photobiomodulation, and Physical Therapy for Achilles Tendinopathy

NCT05751785
View directory record Official record
Conditions
Achilles Tendinopathy
Interventions
Physical Therapy, Shockwave Therapy, Photobiomodulation Therapy
Other · Device
Lead sponsor
Musculoskeletal Injury Rehabilitation Research for Operational Readiness
Federal
Eligibility
18 Years to 64 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 29, 2026, 5:58 PM EDT
Withdrawn Not applicable Interventional

Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study B

NCT03519360
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
UFR-restricted dialysis, UFR-unrestricted dialysis
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 29, 2026, 5:58 PM EDT
Not yet recruiting Not applicable Interventional

Personalized Closed-Loop Brain Stimulation for Patients With Primary Progressive Aphasia

NCT07511179
View directory record Official record
Conditions
PPA
Interventions
Active tES, Cognitive Interventions
Device · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 29, 2026, 5:58 PM EDT
Active, not recruiting Phase 2 Interventional

Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma

NCT03971461
View directory record Official record
Conditions
Meningioma
Interventions
Lutathera
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 29, 2026, 5:58 PM EDT
Active, not recruiting No phase listed Interventional

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

NCT00935090
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
3'-deoxy-3'-[18F]fluorothymidine
Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 29, 2026, 5:58 PM EDT
Completed Not applicable Interventional

Feasibility of an Exercise Intervention

NCT01984060
View directory record Official record
Conditions
HIV
Interventions
HOME-EX
Other
Lead sponsor
University of Rochester
Other
Eligibility
45 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 29, 2026, 5:58 PM EDT
Completed Phase 1 Interventional

A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)

NCT04846920
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Belzutifan
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 29, 2026, 5:58 PM EDT
Completed Phase 3 Interventional Results available

A Study in Second Line Metastatic Colorectal Cancer

NCT01183780
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Ramucirumab, Placebo, Irinotecan, Folinic Acid, 5-Fluorouracil
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,072 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
92
States / cities
Sedona, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 89 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 29, 2026, 5:58 PM EDT
Active, not recruiting Not applicable Interventional

Efficacy Trial of the CALM Intervention

NCT04693858
View directory record Official record
Conditions
Anxiety Disorder of Childhood
Interventions
Child Anxiety Learning Modules (CALM), Child Anxiety Learning Modules--Relaxation (CALM-R)
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
5 Years to 12 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
West Hartford, Connecticut • Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 29, 2026, 5:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Postural Instability in Progressive Supranuclear Palsy

NCT01563276
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Parkinson's Disease
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
40 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 29, 2026, 5:58 PM EDT
Completed Not applicable Interventional

Effects of Soft Robotic Exosuit on Exercise Capacity, Biomakers of Neuroplasticity, and Motor Learning After Stroke

NCT05138016
View directory record Official record
Conditions
Stroke
Interventions
Soft exosuit, No Soft exosuit
Device · Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts • Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 29, 2026, 5:58 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours

NCT05397171
View directory record Official record
Conditions
Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
Interventions
AZD8853, Zirconium-89 crefmirlimab berdoxam
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Atlanta, Georgia • St Louis, Missouri • Providence, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 29, 2026, 5:58 PM EDT
Terminated Phase 2 Interventional Results available

ACTH in Progressive Forms of MS

NCT01950234
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Interventions
ACTH, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
Minneapolis, Minnesota • Fargo, North Dakota • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 29, 2026, 5:58 PM EDT
Completed Not applicable Interventional

Testing a Cognitive Behavioral Model for Reducing Dyspnea in Patients With Lung Cancer

NCT05304793
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Lung Small Cell Carcinoma
Interventions
Best Practice, Cognitive Behavior Therapy, Questionnaire Administration
Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 29, 2026, 5:58 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

NCT01841736
View directory record Official record
Conditions
Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor, Midgut Neuroendocrine Tumor G1, Neuroendocrine Tumor G2, Recurrent Digestive System Neuroendocrine Tumor G1, Regional Digestive System Neuroendocrine Tumor G1
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pazopanib Hydrochloride, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
412
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Anaheim, California + 263 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 29, 2026, 5:58 PM EDT
Terminated Phase 1 Interventional Results available

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma

NCT03704298
View directory record Official record
Conditions
Relapsed/Refractory Large B-cell Lymphoma
Interventions
Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel, Utomilumab
Drug · Biological
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Palo Alto, California • Santa Monica, California • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 29, 2026, 5:58 PM EDT
Terminated Phase 3 Interventional Results available

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

NCT02654587
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
OSE2101, Docetaxel, Pemetrexed
Biological · Drug
Lead sponsor
OSE Immunotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Burbank, California • Washington D.C., District of Columbia • Boca Raton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 29, 2026, 5:58 PM EDT
Completed Phase 2 Interventional

Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue

NCT00004914
View directory record Official record
Conditions
Anemia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
epoetin alfa, physical therapy
Biological · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 29, 2026, 5:58 PM EDT
Terminated Phase 1 Interventional

TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

NCT02650635
View directory record Official record
Conditions
Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Melanoma of the Skin, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Renal Cell Carcinoma, Solid Neoplasm, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Colorectal Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Pancreatic Cancer
Interventions
Cyclophosphamide, Laboratory Biomarker Analysis, Pegfilgrastim, Pharmacological Study, TLR8 Agonist VTX-2337
Drug · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 29, 2026, 5:58 PM EDT